Can risperidone cause depressive mood?

Can Risperidone Cause Depressed Mood?

Yes, risperidone can cause depressed mood and depressive symptoms, though this adverse effect is not consistently listed among the most common side effects in FDA labeling for its primary indications.

Evidence from FDA Drug Labeling

The FDA label for risperidone does not list depression or depressed mood among the most frequently reported adverse reactions (≥2-5% threshold) in controlled trials for schizophrenia, bipolar mania, or autism 1. The psychiatric adverse reactions most commonly reported include insomnia, anxiety, and agitation rather than depression. However, the absence from the "common" adverse reaction tables does not mean depression cannot occur—it simply occurred at rates below the reporting threshold in the pivotal trials.

Clinical Research Evidence

The research literature provides stronger evidence that risperidone can indeed cause or worsen depressive symptoms:

• In a retrospective study of 58 patients with Tourette's disorder treated with risperidone, 29.3% developed major depressive disorder (MDD) and 22.4% became dysphoric while taking the medication 2. Notably, 70% of those who developed depression or dysphoria discontinued risperidone specifically because of this adverse effect. A positive personal history of MDD was the only significant predictor (p<0.001) of developing depression on risperidone.

• A randomized controlled trial in cocaine-dependent men found that those assigned to risperidone reported significantly worsened depressive symptoms compared to placebo (mean HAM-D change: +7.4 vs. -2.3, p=0.018) 3.

• A case report documented risperidone-induced psychosis and increased depression in an adolescent with a mitochondrial disorder, with complete resolution of symptoms within 48 hours of discontinuation 4.

Important Clinical Context

The relationship between risperidone and mood is complex and context-dependent:

While risperidone can cause depression in some patients, it paradoxically improves depressive symptoms in patients with schizophrenia who have comorbid depression 5, 6. This appears related to its effects on the rostral anterior cingulate cortex and overall improvement in psychotic symptoms. Risperidone is even used as augmentation therapy for treatment-resistant depression 7, 8.

Risk Factors and Clinical Approach

Key risk factors for risperidone-induced depression include:

• Prior history of major depressive disorder (strongest predictor) 2
• Mitochondrial disorders 4
• Use in non-psychotic populations (e.g., Tourette's disorder, substance use disorders)

Monitor patients closely for:

• Emergence of depressed mood, anhedonia, or dysphoria
• Worsening of pre-existing depressive symptoms
• Suicidal ideation (particularly in the first 1-2 months, as with all antipsychotics)

If depression emerges on risperidone:

1. Assess whether this represents new-onset depression or worsening of pre-existing symptoms
2. Rule out other causes (extrapyramidal symptoms causing secondary depression, sedation, metabolic effects)
3. Consider dose reduction if clinically appropriate
4. If depression persists or worsens, switch to an alternative antipsychotic with lower risk of mood effects
5. In patients with prior depression history, consider prophylactic antidepressant co-treatment or selecting an alternative antipsychotic initially

The guideline literature 9 lists common risperidone side effects (extrapyramidal symptoms, weight gain, sedation, metabolic effects) but does not specifically highlight depression, likely because it was not prominent in the pediatric schizophrenia trials that informed these guidelines.